{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:38:43Z","timestamp":1794364723355,"version":"4.9.0"},"publisher-location":"Chichester, UK","reference-count":51,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007004.pub2","type":"reference-entry","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T07:11:38Z","timestamp":1246605098000},"source":"Crossref","is-referenced-by-count":20,"title":["Aldosterone antagonists for preventing the progression of chronic kidney disease"],"prefix":"10.1002","author":[{"given":"Sankar D","family":"Navaneethan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini R","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD007004.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007004.pub2-BIB2|cit2","first-page":"33A","article-title":"Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [Abstract]","volume":"17","author":"Bianchi","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD007004.pub2-BIB3|cit3","first-page":"A137","article-title":"A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [Abstract]","volume":"10","author":"Chrysostomou","year":"2005","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007004.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007004.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]","volume":"15","author":"Epstein","year":"2002","journal-title":"American Journal of Hypertension"},{"issue":"Nov","key":"10.1002\/14651858.CD007004.pub2-BIB6|cit6","first-page":"6A","article-title":"The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [Abstract]","volume":"14","author":"Epstein","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertension Research"},{"key":"10.1002\/14651858.CD007004.pub2-BIB9|cit9","first-page":"58A","article-title":"Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone; One year follow up. [Abstract]","volume":"15","author":"Furumatsu","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007004.pub2-BIB10|cit10","first-page":"762A","article-title":"Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone. [Abstract]","volume":"14","author":"Furumatsu","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007004.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"Meiracker","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD007004.pub2-BIB14|cit14","first-page":"57A","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [Abstract]","volume":"16","author":"Schjoedt","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney International"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007004.pub2-BIB16|cit16","first-page":"vi259","article-title":"The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [Abstract]","volume":"22","author":"Larczynski","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.ki.5002511","article-title":"Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney","volume":"72","author":"Tylicki","year":"2007","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD007004.pub2-BIB20|cit19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1464-5491.2006.01969.x","article-title":"Retraction","volume":"23","year":"2006","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub2-BIB19|cit20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabetic Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007004.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007004.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1523-1755.2003.t01-2-00052.x","article-title":"Retarding the progression of renal disease","volume":"64","author":"Brenner","year":"2003","journal-title":"Kidney International"},{"issue":"17","key":"10.1002\/14651858.CD007004.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"issue":"6964","key":"10.1002\/14651858.CD007004.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"9069","key":"10.1002\/14651858.CD007004.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/ndt\/gfi159","article-title":"ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends","volume":"20","author":"Grassmann","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"Journal of Clinical Investigation"},{"issue":"7414","key":"10.1002\/14651858.CD007004.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007004.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD007004.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007004.pub2-BIB35|cit35","series-title":"Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)","article-title":"Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE","author":"Lefebvre","year":"1996"},{"key":"10.1002\/14651858.CD007004.pub2-BIB36|cit36","unstructured":"United States Cochrane Center Master list of journals being searched http:\/\/apps1.jhsph.edu\/cochrane\/masterlist.asp"},{"issue":"7201","key":"10.1002\/14651858.CD007004.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00524.2007","article-title":"Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome","volume":"294","author":"Nakhoul","year":"2008","journal-title":"American Journal of Physiology - Renal Physiology"},{"issue":"15","key":"10.1002\/14651858.CD007004.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Teo","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD007004.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Archives of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007004.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD007004.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"Zeeuw","year":"2004","journal-title":"Kidney International"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD007004.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1046\/j.1523-1755.2003.00340.x","article-title":"The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises","volume":"64","author":"Schieppati","year":"2003","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","article-title":"Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation","volume":"273","author":"Silvestre","year":"1998","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"Journal of Endocrinology"},{"issue":"10","key":"10.1002\/14651858.CD007004.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1681\/ASN.2004080634","article-title":"Antihypertensive agents for primary prevention of diabetic nephropathy","volume":"16","author":"Strippoli","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub2-BIB49|cit49","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub2-BIB50|cit50","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Navaneethan","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007004.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T00:00:00Z","timestamp":1398729600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007004.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:06:13Z","timestamp":1628532373000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007004.pub2"}},"subtitle":[],"editor":[{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007004.pub2","relation":{},"subject":[],"published":{"date-parts":[[2009,7,8]]}}}